Nicole Grunenberg

Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa — South Africa

Immunology and Microbiology · Life Sciences

19h-index1.4kcitations47works4.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(31), vaccines and immunoinformatics approaches(13), HIV/AIDS Research and Interventions(10), SARS-CoV-2 and COVID-19 Research(8), Vaccine Coverage and Hesitancy(7)

Publications44 total

A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials
Emerging Microbes & Infections·2025· 1 citedOpen Access
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1–2 randomized double-blind placebo-controlled trial
PLOS Global Public Health·2024Open Access
Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses
Viruses·2024· 2 citedOpen Access
Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702
Vaccine·2024· 1 citedOpen Access
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial
JAIDS Journal of Acquired Immune Deficiency Syndromes·2024· 5 citedOpen Access
Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial
The Lancet HIV·2024· 9 citedOpen Access
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial
PLoS Medicine·2024· 8 citedOpen Access
An HIV-1 gp41 peptide-liposome vaccine elicits neutralizing epitope-targeted antibody responses in healthy individuals
2024· 6 citedOpen Access
Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial
EBioMedicine·2024· 5 citedOpen Access
Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021
UNC Libraries·2023Open Access
Efficacy of Messenger RNA–1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021
Open Forum Infectious Diseases·2023· 2 citedOpen Access
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120
The Journal of Infectious Diseases·2023· 6 citedOpen Access
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
The Lancet Respiratory Medicine·2023· 23 citedOpen Access
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
EClinicalMedicine·2023· 11 citedOpen Access
Sexually transmitted infections amongst men who have sex with men (MSM) in South Africa
PLOS Global Public Health·2023· 14 citedOpen Access
Risk Factors Associated with HIV Acquisition in Males Participating in HIV Vaccine Efficacy Trials in South Africa
AIDS and Behavior·2023· 3 citedOpen Access
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine
2022· 15 citedOpen Access
Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk
Zenodo (CERN European Organization for Nuclear Research)·2022Open Access
Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk
The Journal of Infectious Diseases·2022· 47 citedOpen Access
Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study
2021· 2 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Lawrence Corey(25), M. Juliana McElrath(23), Peter B. Gilbert(23), Georgia D. Tomaras(21), Fatima Laher(20), James G. Kublin(19), Glenda Gray(18), Linda‐Gail Bekker(17), Kelly E. Seaton(16), Mary Allen(14), Yunda Huang(14), Craig Innes(14), Zoe Moodie(13), Marguerite Koutsoukos(13), Carlos A. DiazGranados(13), David C. Montefiori(12), Lindsey R. Baden(11), Erica Andersen‐Nissen(11), Guido Ferrari(10), Mookho Malahleha(9)